Gemina Laboratories (XCNQ:GLAB) Debt-to-Equity : -0.75 (As of Oct. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Gemina Laboratories Debt-to-Equity?

Gemina Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2023 was C$0.28 Mil. Gemina Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2023 was C$0.23 Mil. Gemina Laboratories's Total Stockholders Equity for the quarter that ended in Oct. 2023 was C$-0.67 Mil. Gemina Laboratories's debt to equity for the quarter that ended in Oct. 2023 was -0.75.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Gemina Laboratories's Debt-to-Equity or its related term are showing as below:

XCNQ:GLAB' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.35 Med: 0.05 Max: 3.31
Current: -0.75

During the past 3 years, the highest Debt-to-Equity Ratio of Gemina Laboratories was 3.31. The lowest was -3.35. And the median was 0.05.

XCNQ:GLAB's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs XCNQ:GLAB: -0.75

Gemina Laboratories Debt-to-Equity Historical Data

The historical data trend for Gemina Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gemina Laboratories Debt-to-Equity Chart

Gemina Laboratories Annual Data

Trend

Jan21

Jan22

Jan23

Debt-to-Equity

0.62

0.05

-3.35

Gemina Laboratories Quarterly Data
	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23
Debt-to-Equity	Get a 7-Day Free Trial						0.24	-3.35	0.16	3.31	-0.75

Competitive Comparison of Gemina Laboratories's Debt-to-Equity

For the Biotechnology subindustry, Gemina Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gemina Laboratories's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gemina Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Gemina Laboratories's Debt-to-Equity falls into.

Gemina Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Gemina Laboratories's Debt to Equity Ratio for the fiscal year that ended in Jan. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.043	+	0.198)	/	-0.072
	=	-3.35

Gemina Laboratories's Debt to Equity Ratio for the quarter that ended in Oct. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.277	+	0.226)	/	-0.67
	=	-0.75

Gemina Laboratories (XCNQ:GLAB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Gemina Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Gemina Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Gemina Laboratories (XCNQ:GLAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gemina Laboratories Ltd (XCNQ:GLAB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

GLABF:USA 8I7:Germany

Address

3800 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8

Website

https://www.geminalabs.com

Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.

Gemina Laboratories (XCNQ:GLAB) Headlines

No Headlines